ONL Therapeutics (ONL) is a biopharmaceutical company committed to protecting and improving the vision of patients with a range of retinal diseases and conditions, including retinal detachment and both the wet and dry forms of age-related macular degeneration (AMD).

By advancing a novel breakthrough technology designed to block programmed cell death (apoptosis), ONL is pioneering an entirely new approach to preserving sight. It is the first and only company focused on preventing the death of key retinal cells, including photoreceptors – the root cause of vision loss, the leading cause of blindness and a completely unaddressed medical need.

Contact Info

Website: http://www.onltherapeutics.com/
E-Mail: info@onltherapeutics.com
Phone: (734) 998-8339

Back to Investments